VIA Pharmaceuticals, Inc.Company Review & Valuation

VIAP
OTC Markets
Latest Price
0.00USD
Market Capitalization
98.68kUSD

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, inShow morecluding vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.Show less

Industry
Biotechnology
HQ Location
San Francisco, California

Stock Price

Price data not available for VIA Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

RedHill Biopharma
Acorda Therapeutics
KalVista Pharmaceuticals
Vertex Pharmaceuticals

back to top